Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Population Pharmacokinetic Model-Based Optimization of Linezolid Dosing in Hematooncological Patients With Suspected or Proven Gram-Positive Sepsis

A. Zavřelová, S. Merdita, P. Žák, J. Radocha, B. Víšek, M. Lánská, J. Maláková, P. Michálek, O. Slanař, M. Šíma

. 2025 ; 18 (9) : e70346. [pub] -

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25021697

Grantová podpora
Ministry of Health

The objective of this study was to develop a population pharmacokinetic model for linezolid in hematooncological patients with sepsis, and to propose dosing optimization based on pharmacokinetic covariates that would lead to improved achievement of the PK/PD target. Therapeutic drug monitoring data from hematooncological patients treated with linezolid for suspected or proven sepsis were analyzed. A pharmacokinetic population model for linezolid was constructed using a nonlinear mixed-effects modeling approach. Monte Carlo simulations were then used to compare various dosing regimens in terms of PK/PD target attainment. A total of 197 linezolid serum concentrations obtained from 22 patients were included in the analysis. Patients' age was found to be the most predictive covariate for linezolid pharmacokinetics. In a patient with a median age of 59 years, the volume of distribution and clearance of linezolid were 46.2 L and 12.1 L/h, respectively. During the first 4 days of therapy, linezolid clearance decreased by 33%. The probability of PK/PD target attainment increased through the individualization of the dose according to the patient's age, administration of a loading dose, and administration of linezolid via continuous infusion. For this scenario, an easy-to-use nomogram was designed.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25021697
003      
CZ-PrNML
005      
20251023075802.0
007      
ta
008      
251014s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1111/cts.70346 $2 doi
035    __
$a (PubMed)40905412
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Zavřelová, Alžběta $u 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
245    10
$a Population Pharmacokinetic Model-Based Optimization of Linezolid Dosing in Hematooncological Patients With Suspected or Proven Gram-Positive Sepsis / $c A. Zavřelová, S. Merdita, P. Žák, J. Radocha, B. Víšek, M. Lánská, J. Maláková, P. Michálek, O. Slanař, M. Šíma
520    9_
$a The objective of this study was to develop a population pharmacokinetic model for linezolid in hematooncological patients with sepsis, and to propose dosing optimization based on pharmacokinetic covariates that would lead to improved achievement of the PK/PD target. Therapeutic drug monitoring data from hematooncological patients treated with linezolid for suspected or proven sepsis were analyzed. A pharmacokinetic population model for linezolid was constructed using a nonlinear mixed-effects modeling approach. Monte Carlo simulations were then used to compare various dosing regimens in terms of PK/PD target attainment. A total of 197 linezolid serum concentrations obtained from 22 patients were included in the analysis. Patients' age was found to be the most predictive covariate for linezolid pharmacokinetics. In a patient with a median age of 59 years, the volume of distribution and clearance of linezolid were 46.2 L and 12.1 L/h, respectively. During the first 4 days of therapy, linezolid clearance decreased by 33%. The probability of PK/PD target attainment increased through the individualization of the dose according to the patient's age, administration of a loading dose, and administration of linezolid via continuous infusion. For this scenario, an easy-to-use nomogram was designed.
650    _2
$a lidé $7 D006801
650    12
$a linezolid $x farmakokinetika $x aplikace a dávkování $7 D000069349
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a senioři $7 D000368
650    12
$a sepse $x farmakoterapie $x mikrobiologie $x diagnóza $x krev $7 D018805
650    _2
$a metoda Monte Carlo $7 D009010
650    12
$a antibakteriální látky $x farmakokinetika $x aplikace a dávkování $7 D000900
650    _2
$a monitorování léčiv $x metody $7 D016903
650    _2
$a dospělí $7 D000328
650    12
$a biologické modely $7 D008954
650    _2
$a senioři nad 80 let $7 D000369
650    12
$a grampozitivní bakteriální infekce $x farmakoterapie $x mikrobiologie $x krev $x diagnóza $7 D016908
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a věkové faktory $7 D000367
655    _2
$a časopisecké články $7 D016428
700    1_
$a Merdita, Sara $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Žák, Pavel $u 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Radocha, Jakub $u 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Víšek, Benjamin $u 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Lánská, Miriam $u 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Maláková, Jana $u Department of Clinical Biochemistry and Diagnostics, University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Michálek, Pavel $u Department of Anaesthesiology, Resuscitation and Intensive Care Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Slanař, Ondřej $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Šíma, Martin $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $1 https://orcid.org/000000026541738X $7 xx0222901
773    0_
$w MED00173319 $t Clinical and translational science $x 1752-8062 $g Roč. 18, č. 9 (2025), s. e70346
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40905412 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20251014 $b ABA008
991    __
$a 20251023075808 $b ABA008
999    __
$a ok $b bmc $g 2416854 $s 1259860
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 18 $c 9 $d e70346 $e - $i 1752-8062 $m Clinical and translational science $n Clin Transl Sci $x MED00173319
GRA    __
$p Ministry of Health
LZP    __
$a Pubmed-20251014

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace